Constitutive Kras and NF-kB activation are indentified as signatures of pancreatic ductal adenocarcinoma and RelAp65/NF-kB is constitutively activated in almost 70% of pancreatic cancer specimens and the inhibition of NF-kB activity inhibits pancreatic cell tumorigenesis [43, 44]. The gene discussed is KRAS; the disease is pancreatic neoplasm.